ELEV 241018 5.00C (ELEV241018C5000) Stock Options, News & Quotes

US OptionsDetailed Quotes

ELEV241018C5000

Watchlist

0.35
0.000.00%

15min DelayClose Oct 1 15:56 ET

0.00High0.00Low

Intraday

5D
Daily

News

12 Health Care Stocks Moving In Friday's After-Market Session
BenzingaSep 27 16:31 ET
Elevation Oncology's EO-3021 Granted FDA Fast Track for Advanced Gastric Cancer Treatment
BenzingaSep 23 07:36 ET
Express News | Elevation Oncology: Look to Advancing Through Monotherapy Dose Expansion, Reporting More Data From Ongoing Trial in H1 2025
ReutersSep 23 07:32 ET
Express News | Elevation Oncology Receives Fast Track Designation From the FDA for Eo-3021 for the Treatment of Adult Patients With Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer Expressing Claudin 18.2
ReutersSep 23 07:30 ET
Express News | Elevation Oncology Inc - on Sept18, Got Notice From Nasdaq on Co's Failure to Satisfy a Continued Listing Rule or Standard
ReutersSep 20 16:25 ET
Elevation Oncology to Present at the H.C. Wainwright 26th Annual Global Investment Conference
PR NewswireSep 3 07:30 ET

Comments

Jaguar8

Sep 23 19:30

NEWS

$Elevation Oncology (ELEV.US)$
Elevation Oncology Receives Fast Track Designation from the FDA for EO-3021 for the Treatment of Adult Patients with Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer Expressing Claudin 18.2

Boxman

Aug 9 09:59

Doing pretty good

$Elevation Oncology (ELEV.US)$ Second Quarter 2024 Financial Results
As of June 30, 2024, Elevation Oncology had cash, cash equivalents and marketable securities totaling $110.8 million, compared to $83.1 million as of December 31, 2023. The increase in cash reflects net proceeds of $44.2 million, which Elevation Oncology raised through its at-the-market (ATM) facility in the first half of 2024, partially offset by cash used to fund operating activities

Boxman

Aug 6 19:39

Elevation Oncology Reports Second Quarter 2024 Financial Results and Highlights Recent Business Achievements

$Elevation Oncology (ELEV.US)$ -- Elevation Oncology to host conference call and webcast today at 8:30 a.m. ET

porsh

Jul 16 22:08

$Elevation Oncology (ELEV.US)$ nice

Trytosaveabit

May 3 18:41

Watching for data!

$Elevation Oncology (ELEV.US)$ Data expected readout of EO-3021 data in the latter half of 2024, which could showcase the efficacy and safety of the anti-Claudin 18.2 antibody-drug conjugate in treating advanced cancers.
Furthermore, preclinical data has shown that Elevation Oncology’s HER3-ADC candidate demonstrates significant antitumor activity, suggesting a strong foundation for future clinical evaluations